Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers

Impact of Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers

The study focus on the impact of estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in women undertaking assisted reproductive technology treatment (ART).

The aim is to investigate whether the coagulation is activated in women undergoing estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in assisted reproductive technology treatment (ART). An activation of the coagulation might induce an increased thromboembolic risk in these women. Thus, the present study may lead to improvement of the current treatment protocol for women receiving AC-FET and ultimately prevent thromboembolic complications for woman in fertility treatment.

Inclusion Criteria:

• Women receiving FET with or without estrogen/progesterone substitution

Exclusion Criteria:

• Known bleeding disorder
• Indication for thromboprophylaxis during ART treatment
• Treatment with anti-platelet medication including non-steroid-anti-inflammatory drugs (NSAIDs) within the last week
• Donor recipients